Illumina, Inc. $ILMN Shares Purchased by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. increased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 217.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,047 shares of the life sciences company’s stock after acquiring an additional 3,457 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Illumina were worth $662,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Elyxium Wealth LLC acquired a new stake in shares of Illumina in the fourth quarter valued at about $25,000. Board of the Pension Protection Fund acquired a new stake in shares of Illumina in the fourth quarter valued at about $26,000. Creative Capital Management Investments LLC lifted its stake in shares of Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 120 shares during the period. TD Waterhouse Canada Inc. acquired a new stake in shares of Illumina in the fourth quarter valued at about $26,000. Finally, Laurel Wealth Advisors LLC acquired a new stake in shares of Illumina in the fourth quarter valued at about $26,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. JPMorgan Chase & Co. upped their price target on Illumina from $120.00 to $125.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. Daiwa Securities Group upgraded Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target on the stock in a report on Thursday, May 14th. Royal Bank Of Canada began coverage on Illumina in a research note on Thursday, May 14th. They set an “outperform” rating and a $170.00 price target for the company. Weiss Ratings raised Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Finally, Citigroup lifted their price target on Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research note on Monday, May 4th. Seven investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Illumina presently has an average rating of “Hold” and an average target price of $138.38.

Insider Buying and Selling

In other Illumina news, SVP Patricia Leckman sold 783 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $162.59, for a total transaction of $127,307.97. Following the sale, the senior vice president owned 21,259 shares in the company, valued at $3,456,500.81. This represents a 3.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of Illumina stock in a transaction on Friday, May 29th. The stock was sold at an average price of $160.00, for a total transaction of $98,400.00. Following the completion of the transaction, the insider directly owned 21,568 shares of the company’s stock, valued at approximately $3,450,880. This represents a 2.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,003,154 shares of company stock worth $155,600,208 over the last 90 days. 2.90% of the stock is currently owned by corporate insiders.

Illumina Stock Up 1.3%

ILMN opened at $160.03 on Wednesday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The stock has a market capitalization of $24.21 billion, a price-to-earnings ratio of 29.10, a price-to-earnings-growth ratio of 2.96 and a beta of 1.50. The business has a 50-day moving average of $139.27 and a two-hundred day moving average of $134.20. Illumina, Inc. has a 12 month low of $85.00 and a 12 month high of $177.22.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the previous year, the business earned $0.97 earnings per share. The firm’s quarterly revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, research analysts expect that Illumina, Inc. will post 5.2 earnings per share for the current year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.